Publications

Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran C.M, Rawcliffe C, Sripadam R, Mukherjee S, Soonawalla Z, Wadsley J, Al-Mukhtar A, Dickson E, Graham J, Jiao L, Wasan H.S, Tait I.S, Prachalias A, Ross P, Valle J.W, O'Reilly D.A, Al-Sarireh B, Gwynne S, Ahmed I, Connolly K, Yim K.L, Cunningham D, Armstrong T, Archer C, Roberts K, Ma Y.T, Springfeld C, Tjaden C, Hackert T, Büchler M.W, Neoptolemos J.P, European Study Group for Pancreatic Cancer. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):157-168. DOI: 10.1016/S2468-1253(22)00348-X